268 related articles for article (PubMed ID: 25744290)
1. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour.
Cahir C; Dombrowski SU; Kelly CM; Kennedy MJ; Bennett K; Sharp L
Support Care Cancer; 2015 Nov; 23(11):3115-30. PubMed ID: 25744290
[TBL] [Abstract][Full Text] [Related]
2. Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer.
Cahir C; Dombrowski SU; Kennedy MJ; Sharp L; Bennett K
Psychol Health; 2017 Oct; 32(10):1308-1326. PubMed ID: 28276740
[TBL] [Abstract][Full Text] [Related]
3. Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: A systematic review and meta-analysis.
Cahir C; Guinan E; Dombrowski SU; Sharp L; Bennett K
Patient Educ Couns; 2015 May; ():. PubMed ID: 26054455
[TBL] [Abstract][Full Text] [Related]
4. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
[TBL] [Abstract][Full Text] [Related]
5. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
6. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
Cahir C; Barron TI; Sharp L; Bennett K
Cancer Causes Control; 2017 Mar; 28(3):215-225. PubMed ID: 28210883
[TBL] [Abstract][Full Text] [Related]
7. Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence.
Cahir C; Bennett K; Dombrowski SU; Kelly CM; Wells M; Watson E; Sharp L
Support Care Cancer; 2023 Mar; 31(3):200. PubMed ID: 36869943
[TBL] [Abstract][Full Text] [Related]
8. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory.
AlOmeir O; Patel N; Donyai P
Support Care Cancer; 2020 Nov; 28(11):5075-5084. PubMed ID: 32601852
[TBL] [Abstract][Full Text] [Related]
10. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
11. More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):998-1018. PubMed ID: 28940998
[TBL] [Abstract][Full Text] [Related]
12. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
13. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer.
Barron TI; Cahir C; Sharp L; Bennett K
Br J Cancer; 2013 Sep; 109(6):1513-21. PubMed ID: 24002590
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
15. "It is not just any pill"-Women's experiences of endocrine therapy after breast cancer surgery.
Ahlstedt Karlsson S; Wallengren C; Olofsson Bagge R; Henoch I
Eur J Cancer Care (Engl); 2019 May; 28(3):e13009. PubMed ID: 30748038
[TBL] [Abstract][Full Text] [Related]
16. Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer.
Corter AL; Findlay M; Broom R; Porter D; Petrie KJ
Br J Health Psychol; 2013 Feb; 18(1):168-81. PubMed ID: 23134580
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: A qualitative systematic review.
Xu H; Zhang XJ; Wang DQ; Xu L; Wang AP
J Adv Nurs; 2020 Feb; 76(2):445-458. PubMed ID: 31657028
[TBL] [Abstract][Full Text] [Related]
18. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
[TBL] [Abstract][Full Text] [Related]
19. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
20. Identifying the barriers and enablers in the implementation of the New Zealand and Australian Antenatal Corticosteroid Clinical Practice Guidelines.
Mc Goldrick EL; Crawford T; Brown JA; Groom KM; Crowther CA
BMC Health Serv Res; 2016 Oct; 16(1):617. PubMed ID: 27793150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
